View Item 

Show simple item record

New approaches to the study of sepsis
dc.contributor.authorWard, Peter A.en_US
dc.date.accessioned2012-12-11T17:37:17Z
dc.date.available2014-02-03T16:21:44Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationWard, Peter A. (2012). "New approaches to the study of sepsis." EMBO Molecular Medicine 4(12): 1234-1243. <http://hdl.handle.net/2027.42/94452>en_US
dc.identifier.issn1757-4676en_US
dc.identifier.issn1757-4684en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/94452
dc.description.abstractModels of sepsis have been instructive in understanding the sequence of events in animals and, to an extent, in humans with sepsis. Events developing early in sepsis suggest that a hyperinflammatory state exists, accompanied by a buildup of oxidants in tissues reflective of a redox imbalance. Development of immunosuppression and degraded innate and adaptive immune responses are well‐established complications of sepsis. In addition, there is robust activation of the complement system, which contributes to the harmful effects of sepsis. These events appear to be associated with development of multiorgan failure. The relevance of animal models of sepsis to human sepsis and the failure of human clinical trials are discussed, together with suggestions as to how clinical trial design might be improved. Currently there is no FDA‐approved drug for use in sepsis. This Review discusses the relevance of animal models to human sepsis and the failure of human clinical trials and provides suggestions as to how clinical trial design might be improved.en_US
dc.publisherWILEY‐VCH Verlagen_US
dc.subject.otherMediatorsen_US
dc.subject.otherClinical Trialsen_US
dc.subject.otherSepsisen_US
dc.subject.otherComplementen_US
dc.subject.otherInterventionsen_US
dc.titleNew approaches to the study of sepsisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherTel: +1 734 647 2921; Fax: +1 734 764 4308en_US
dc.identifier.pmid23208733en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/94452/1/1234_ftp.pdf
dc.identifier.doi10.1002/emmm.201201375en_US
dc.identifier.sourceEMBO Molecular Medicineen_US
dc.identifier.citedreferenceSpeyer CL, Ward PA ( 2011 ) Role of endothelial chemokines and their receptors during inflammation. J Invest Surg 24: 18 ‐ 27en_US
dc.identifier.citedreferenceSportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, et al ( 2008 ) Administration of rhIL‐7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205: 1701 ‐ 1714en_US
dc.identifier.citedreferenceStevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA ( 1986 ) Effects of anti‐C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 77: 1812 ‐ 1816en_US
dc.identifier.citedreferenceTang CH, Middleton PM, Savkin AV, Chan GS, Bishop S, Lovell NH ( 2010 ) Non‐invasive classification of severe sepsis and systemic inflammatory response syndrome using a nonlinear support vector machine: a preliminary study. Physiol Meas 31: 775 ‐ 793en_US
dc.identifier.citedreferenceTracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A ( 1987 ) Anti‐cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662 ‐ 664en_US
dc.identifier.citedreferenceUnsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, et al ( 2010 ) IL‐7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 184: 3768 ‐ 3779en_US
dc.identifier.citedreferenceVetvicka V ( 2011 ) Glucan‐immunostimulant, adjuvant, potential drug. World J Clin Oncol 2: 115 ‐ 119en_US
dc.identifier.citedreferenceVincent JL, Sun Q, Dubois MJ ( 2002 ) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34: 1084 ‐ 1093en_US
dc.identifier.citedreferenceWard PA ( 2004 ) The dark side of C5a in sepsis. Nat Rev Immunol 4: 133 ‐ 142en_US
dc.identifier.citedreferenceWard PA ( 2010 ) The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2: 439 ‐ 445en_US
dc.identifier.citedreferenceWebster NR, Galley HF ( 2009 ) Immunomodulation in the critically ill. Br J Anaesth 103: 70 ‐ 81en_US
dc.identifier.citedreferenceWichmann MW, Inthorn D, Andress HJ, Schildberg FW ( 2000 ) Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 26: 167 ‐ 172en_US
dc.identifier.citedreferenceWinchester JF, Kellum JA, Ronco C, Brady JA, Quartararo PJ, Salsberg JA, Levin NW ( 2003 ) Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif 21: 79 ‐ 84en_US
dc.identifier.citedreferenceWinters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE ( 2010 ) Long‐term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38: 1276 ‐ 1283en_US
dc.identifier.citedreferenceWoodruff TM, Nandakumar KS, Tedesco F ( 2011 ) Inhibiting the C5‐C5a receptor axis. Mol Immunol 48: 1631 ‐ 1642en_US
dc.identifier.citedreferenceWrann CD, Winter SW, Barkhausen T, Hildebrand F, Krettek C, Riedemann NC ( 2007 ) Distinct involvement of p38‐, ERK1/2 and PKC signaling pathways in C5a‐mediated priming of oxidative burst in phagocytic cells. Cell Immunol 245: 63 ‐ 69en_US
dc.identifier.citedreferenceWu R, Xu Y, Song X, Meng X ( 2002 ) Gene expression of adhesion molecules in pulmonary and hepatic microvascular endothelial cells during sepsis. Chin J Traumatol 5: 146 ‐ 150en_US
dc.identifier.citedreferenceYachamaneni S, Yushin G, Yeon SH, Gogotsi Y, Howell C, Sandeman S, Phillips G, Mikhalovsky S ( 2010 ) Mesoporous carbide‐derived carbon for cytokine removal from blood plasma. Biomaterials 31: 4789 ‐ 4794en_US
dc.identifier.citedreferenceYang D, de la Rosa G, Tewary P, Oppenheim JJ ( 2009 ) Alarmins link neutrophils and dendritic cells. Trends Immunol 30: 531 ‐ 537en_US
dc.identifier.citedreferenceZanotti‐Cavazzoni SL, Goldfarb RD ( 2009 ) Animal models of sepsis. Crit Care Clin 25: 703 ‐ 719, vii–viiien_US
dc.identifier.citedreferenceZipfel C, Robatzek S ( 2010 ) Pathogen‐associated molecular pattern‐triggered immunity: veni, vidi... ? Plant Physiol 154: 551 ‐ 554en_US
dc.identifier.citedreferenceAdrie C, Azoulay E, Francais A, Clec'h C, Darques L, Schwebel C, Nakache D, Jamali S, Goldgran‐Toledano D, Garrouste‐Orgeas M, et al ( 2007 ) Influence of gender on the outcome of severe sepsis: a reappraisal. Chest 132: 1786 ‐ 1793en_US
dc.identifier.citedreferenceAngus DC ( 2010 ) The lingering consequences of sepsis: a hidden public health disaster ? JAMA 304: 1833 ‐ 1834en_US
dc.identifier.citedreferenceAngus DC ( 2011 ) The search for effective therapy for sepsis: back to the drawing board ? JAMA 306: 2614 ‐ 2615en_US
dc.identifier.citedreferenceAngus DC, Linde‐Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR ( 2001 ) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303 ‐ 1310en_US
dc.identifier.citedreferenceBagshaw SM ( 2008 ) Short‐ and long‐term survival after acute kidney injury. Nephrol Dial Transplant 23: 2126 ‐ 2128en_US
dc.identifier.citedreferenceBanks WA ( 2008 ) The blood‐brain barrier: connecting the gut and the brain. Regul Pept 149: 11 ‐ 14en_US
dc.identifier.citedreferenceBeutler B, Milsark IW, Cerami AC ( 1985 ) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869 ‐ 871en_US
dc.identifier.citedreferenceBianchi ME ( 2007 ) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81: 1 ‐ 5en_US
dc.identifier.citedreferenceBoomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD II, Kreisel D, Krupnick AS, et al ( 2011 ) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306: 2594 ‐ 2605en_US
dc.identifier.citedreferenceBuras JA, Holzmann B, Sitkovsky M ( 2005 ) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4: 854 ‐ 865en_US
dc.identifier.citedreferenceChen GY, Nunez G ( 2010 ) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826 ‐ 837en_US
dc.identifier.citedreferenceChen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H, Yeh WC ( 2007 ) C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446: 203 ‐ 207en_US
dc.identifier.citedreferenceChoudhry MA, Bland KI, Chaudry IH ( 2006 ) Gender and susceptibility to sepsis following trauma. Endocr Metab Immune Disord Drug Targets 6: 127 ‐ 135en_US
dc.identifier.citedreferenceClark JA, Coopersmith CM ( 2007 ) Intestinal crosstalk: a new paradigm for understanding the gut as the “motor” of critical illness. Shock 28: 384 ‐ 393en_US
dc.identifier.citedreferenceCole L, Bellomo R, Davenport P, Tipping P, Uchino S, Tetta C, Ronco C ( 2002 ) The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 17: 1950 ‐ 1956en_US
dc.identifier.citedreferenceCruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al ( 2009 ) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301: 2445 ‐ 2452en_US
dc.identifier.citedreferenceDeitch EA ( 1998 ) Animal models of sepsis and shock: a review and lessons learned. Shock 9: 1 ‐ 11en_US
dc.identifier.citedreferenceDeitch EA ( 2002 ) Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings ? Surgery 131: 241 ‐ 244en_US
dc.identifier.citedreferenceDejager L, Pinheiro I, Dejonckheere E, Libert C ( 2011 ) Cecal ligation and puncture: the gold standard model for polymicrobial sepsis ? Trends Microbiol 19: 198 ‐ 208en_US
dc.identifier.citedreferenceDevoy A, Bunton‐Stasyshyn RK, Tybulewicz VL, Smith AJ, Fisher EM ( 2012 ) Genomically humanized mice: technologies and promises. Nat Rev Genet 13: 14 ‐ 20en_US
dc.identifier.citedreferenceDoi K, Leelahavanichkul A, Yuen PS, Star RA ( 2009 ) Animal models of sepsis and sepsis‐induced kidney injury. J Clin Invest 119: 2868 ‐ 2878en_US
dc.identifier.citedreferenceDyson A, Singer M ( 2009 ) Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting ? Crit Care Med 37: S30 ‐ S37en_US
dc.identifier.citedreferenceEachempati SR, Hydo L, Barie PS ( 1999 ) Gender‐based differences in outcome in patients with sepsis. Arch Surg 134: 1342 ‐ 1347en_US
dc.identifier.citedreferenceEskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG ( 1992 ) Anti‐tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148: 2724 ‐ 2730en_US
dc.identifier.citedreferenceFang FC ( 2004 ) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2: 820 ‐ 832en_US
dc.identifier.citedreferenceFink MP ( 2008 ) Animal models of sepsis and its complications. Kidney Int 74: 991 ‐ 993en_US
dc.identifier.citedreferenceFink MP, Heard SO ( 1990 ) Laboratory models of sepsis and septic shock. J Surg Res 49: 186 ‐ 196en_US
dc.identifier.citedreferenceFry TJ, Mackall CL ( 2005 ) The many faces of IL‐7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 174: 6571 ‐ 6576en_US
dc.identifier.citedreferenceGeiselhart LA, Humphries CA, Gregorio TA, Mou S, Subleski J, Komschlies KL ( 2001 ) IL‐7 administration alters the CD4: CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol 166: 3019 ‐ 3027en_US
dc.identifier.citedreferenceGerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C ( 2005 ) An anti‐inflammatory function for the complement anaphylatoxin C5a‐binding protein, C5L2. J Biol Chem 280: 39677 ‐ 39680en_US
dc.identifier.citedreferenceGertsch J, Viveros‐Paredes JM, Taylor P ( 2011 ) Plant immunostimulants – scientific paradigm or myth ? J Ethnopharmacol 136: 385 ‐ 391en_US
dc.identifier.citedreferenceGuo RF, Ward PA ( 2005 ) Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821 ‐ 852en_US
dc.identifier.citedreferenceHermans G, De Jonghe B, Bruyninckx F, Van den Berghe G ( 2008 ) Clinical review: critical illness polyneuropathy and myopathy. Crit Care 12: 238 ‐ 246en_US
dc.identifier.citedreferenceHiromatsu T, Yajima T, Matsuguchi T, Nishimura H, Wajjwalku W, Arai T, Nimura Y, Yoshikai Y ( 2003 ) Overexpression of interleukin‐15 protects against Escherichia coli ‐induced shock accompanied by inhibition of tumor necrosis factor‐alpha‐induced apoptosis. J Infect Dis 187: 1442 ‐ 1451en_US
dc.identifier.citedreferenceHotchkiss RS, Karl IE ( 2003 ) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138 ‐ 150en_US
dc.identifier.citedreferenceHotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE ( 1999 ) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 96: 14541 ‐ 14546en_US
dc.identifier.citedreferenceHuber‐Lang MS, Sarma JV, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, Younkin EM, Laudes IJ, Riedemann NC, Younger JG, et al ( 2001 ) Protective effects of anti‐C5a peptide antibodies in experimental sepsis. FASEB J 15: 568 ‐ 570en_US
dc.identifier.citedreferenceLaudes IJ, Guo RF, Riedemann NC, Speyer C, Craig R, Sarma JV, Ward PA ( 2004 ) Disturbed homeostasis of lung intercellular adhesion molecule‐1 and vascular cell adhesion molecule‐1 during sepsis. Am J Pathol 164: 1435 ‐ 1445en_US
dc.identifier.citedreferenceMarshall JC ( 2008 ) Sepsis: rethinking the approach to clinical research. J Leukoc Biol 83: 471 ‐ 482en_US
dc.identifier.citedreferenceMonk PN, Scola AM, Madala P, Fairlie DP ( 2007 ) Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152: 429 ‐ 448en_US
dc.identifier.citedreferenceNakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H ( 2008 ) Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 14: 257 ‐ 263en_US
dc.identifier.citedreferenceO'Reilly T, Zak O ( 1992 ) Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis 14: 1100 ‐ 1109en_US
dc.identifier.citedreferenceOkinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, Brodbeck RM, Krause JE, Choe HR, Gerard NP, et al ( 2003 ) C5L2, a nonsignaling C5A binding protein. Biochemistry 42: 9406 ‐ 9415en_US
dc.identifier.citedreferenceOpal SM ( 2002 ) The clinical relevance of endotoxin in human sepsis: a critical analysis. J Endotoxin Res 8: 473 ‐ 476en_US
dc.identifier.citedreferenceOppenheim JJ, Tewary P, de la Rosa G, Yang D ( 2007 ) Alarmins initiate host defense. Adv Exp Med Biol 601: 185 ‐ 194en_US
dc.identifier.citedreferencePardo M, Budick‐Harmelin N, Tirosh B, Tirosh O ( 2008 ) Antioxidant defense in hepatic ischemia‐reperfusion injury is regulated by damage‐associated molecular pattern signal molecules. Free Radic Biol Med 45: 1073 ‐ 1083en_US
dc.identifier.citedreferenceRanzani OT, Ferrer M, Esperatti M, Giunta V, Bassi GL, Carvalho CR, Torres A ( 2012 ) Association between systemic corticosteroids and outcomes of intensive care unit‐acquired pneumonia. Crit Care Med 40: 2552 ‐ 2561en_US
dc.identifier.citedreferenceRemick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G ( 1995 ) Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4: 89 ‐ 95en_US
dc.identifier.citedreferenceRemick DG, Ward PA ( 2005 ) Evaluation of endotoxin models for the study of sepsis. Shock 24 (Suppl 1): 7 ‐ 11en_US
dc.identifier.citedreferenceRittirsch D, Flierl MA, Nadeau BA, Day DE, Huber‐Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianflone K, Kohl J, et al ( 2008 ) Functional roles for C5a receptors in sepsis. Nat Med 14: 551 ‐ 557en_US
dc.identifier.citedreferenceRittirsch D, Hoesel LM, Ward PA ( 2007 ) The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81: 137 ‐ 143en_US
dc.identifier.citedreferenceRittirsch D, Huber‐Lang MS, Flierl MA, Ward PA ( 2009 ) Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4: 31 ‐ 36en_US
dc.identifier.citedreferenceRussell JA ( 2006 ) Management of sepsis. N Engl J Med 355: 1699 ‐ 1713en_US
dc.identifier.citedreferenceSchroder J, Kahlke V, Staubach KH, Zabel P, Stuber F ( 1998 ) Gender differences in human sepsis. Arch Surg 133: 1200 ‐ 1205en_US
dc.identifier.citedreferenceSchultz MJ, van der Poll T ( 2002 ) Animal and human models for sepsis. Ann Med 34: 573 ‐ 581en_US
dc.identifier.citedreferenceSchumer W ( 1976 ) Steroids in the treatment of clinical septic shock. Ann Surg 184: 333 ‐ 341en_US
dc.identifier.citedreferenceShimizu T, Endo Y, Tsuchihashi H, Akabori H, Yamamoto H, Tani T ( 2006 ) Endotoxin apheresis for sepsis. Transfus Apher Sci 35: 271 ‐ 282en_US
dc.identifier.citedreferenceSieberth HG, Kierdorf HP ( 1999 ) Is cytokine removal by continuous hemofiltration feasible ? Kidney Int 72 (Suppl): S79 ‐ S83en_US
dc.identifier.citedreferenceSpeyer CL, Gao H, Rancilio NJ, Neff TA, Huffnagle GB, Sarma JV, Ward PA ( 2004 ) Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 165: 2187 ‐ 2196en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
1234_ftp.pdf
Size:
484.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.